Literature DB >> 32805923

Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro.

Ridhima Juneja1, Hemapriyadarshini Vadarevu1,2, Justin Halman1,2, Mubin Tarannum1,2, Lauren Rackley1, Jacob Dobbs1, Jose Marquez1, Morgan Chandler1,2, Kirill Afonin1,2,3, Juan L Vivero-Escoto1,2,3.   

Abstract

Programmable nucleic acid nanoparticles (class="Gene">NANPs) with class="Chemical">precisely controlled functional comclass="Chemical">positions can regulate the conditional activation of various biological class="Chemical">pathways and resclass="Chemical">ponses in class="Chemical">pan class="Species">human cells. However, the intracellular delivery of NANPs alone is hindered by their susceptibility to nuclease activity and inefficient crossing of biological membranes. In this work, we optimized the internalization and therapeutic performance of several representative NANPs delivered with mesoporous silica nanoparticles (MSNPs) tailored for efficient electrostatic association with NANPs. We compared the immunostimulatory properties of different NA-MS-NP complexes formed with globular, planar, and fibrous NANPs and demonstrated the maximum immunostimulation for globular NANPs. As a proof of concept, we assessed the specific gene silencing by NA-MS-NP complexes functionalized with siRNA targeting green fluorescent protein expressed in triple-negative human breast cancer cells. We showed that the fibrous NANPs have the highest silencing efficiency when compared to globular or planar counterparts. Finally, we confirmed the multimodal ability of MSNPs to co-deliver a chemotherapy drug, doxorubicin, and NANPs targeting apoptosis regulator gene BCL2 in triple-negative breast cancer and melanoma cell lines. Overall, the combination of NANPs and MSNPs may become a new promising approach to efficiently treat cancer and other diseases via the simultaneous targeting of various pathways.

Entities:  

Keywords:  combination therapy; doxorubicin; melanoma; mesoporous silica nanoparticles (MSNPs); nucleic acid nanoparticles (NANPs); small interfering RNA; triple-negative breast cancer

Mesh:

Substances:

Year:  2020        PMID: 32805923      PMCID: PMC7748385          DOI: 10.1021/acsami.0c07106

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  69 in total

Review 1.  Degradability and Clearance of Silicon, Organosilica, Silsesquioxane, Silica Mixed Oxide, and Mesoporous Silica Nanoparticles.

Authors:  Jonas G Croissant; Yevhen Fatieiev; Niveen M Khashab
Journal:  Adv Mater       Date:  2017-01-13       Impact factor: 30.849

2.  Endosomal escape kinetics of mesoporous silica-based system for efficient siRNA delivery.

Authors:  Mingqi Wang; Xu Li; Yongjie Ma; Hongchen Gu
Journal:  Int J Pharm       Date:  2013-03-19       Impact factor: 5.875

Review 3.  Recent advances in porous nanoparticles for drug delivery in antitumoral applications: inorganic nanoparticles and nanoscale metal-organic frameworks.

Authors:  Alejandro Baeza; Daniel Ruiz-Molina; María Vallet-Regí
Journal:  Expert Opin Drug Deliv       Date:  2016-09-09       Impact factor: 6.648

Review 4.  The emerging field of RNA nanotechnology.

Authors:  Peixuan Guo
Journal:  Nat Nanotechnol       Date:  2010-11-21       Impact factor: 39.213

5.  Structure and Composition Define Immunorecognition of Nucleic Acid Nanoparticles.

Authors:  Enping Hong; Justin R Halman; Ankit B Shah; Emil F Khisamutdinov; Marina A Dobrovolskaia; Kirill A Afonin
Journal:  Nano Lett       Date:  2018-06-20       Impact factor: 11.189

6.  Computational and experimental characterization of RNA cubic nanoscaffolds.

Authors:  Kirill A Afonin; Wojciech Kasprzak; Eckart Bindewald; Praneet S Puppala; Alex R Diehl; Kenneth T Hall; Tae Jin Kim; Michael T Zimmermann; Robert L Jernigan; Luc Jaeger; Bruce A Shapiro
Journal:  Methods       Date:  2013-11-01       Impact factor: 3.608

7.  Silatrane-based surface chemistry for immobilization of DNA, protein-DNA complexes and other biological materials.

Authors:  Luda S Shlyakhtenko; Alexander A Gall; Alexander Filonov; Zoran Cerovac; Alexander Lushnikov; Yuri L Lyubchenko
Journal:  Ultramicroscopy       Date:  2003 Oct-Nov       Impact factor: 2.689

8.  In silico design and enzymatic synthesis of functional RNA nanoparticles.

Authors:  Kirill A Afonin; Wojciech K Kasprzak; Eckart Bindewald; Maria Kireeva; Mathias Viard; Mikhail Kashlev; Bruce A Shapiro
Journal:  Acc Chem Res       Date:  2014-04-23       Impact factor: 22.384

9.  Erratum: Hong, E., et al. Toll-Like Receptor-Mediated Recognition of Nucleic Acid Nanoparticles (NANPs) in Human Primary Blood Cells. Molecules 2019, 24, 1094.

Authors:  Enping Hong; Justin R Halman; Ankit Shah; Edward Cedrone; Nguyen Truong; Kirill A Afonin; Marina A Dobrovolskaia
Journal:  Molecules       Date:  2019-10-25       Impact factor: 4.411

10.  Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification.

Authors:  Amy Chan; Abigail Liebow; Makiko Yasuda; Lin Gan; Tim Racie; Martin Maier; Satya Kuchimanchi; Don Foster; Stuart Milstein; Klaus Charisse; Alfica Sehgal; Muthiah Manoharan; Rachel Meyers; Kevin Fitzgerald; Amy Simon; Robert J Desnick; William Querbes
Journal:  Mol Ther Nucleic Acids       Date:  2015-11-03       Impact factor: 10.183

View more
  8 in total

Review 1.  To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives.

Authors:  Da Shi; Damian Beasock; Adam Fessler; Janos Szebeni; Julia Y Ljubimova; Kirill A Afonin; Marina A Dobrovolskaia
Journal:  Adv Drug Deliv Rev       Date:  2021-12-10       Impact factor: 15.470

Review 2.  The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize.

Authors:  Miroslaw Janowski; Anna Andrzejewska
Journal:  Mol Ther Nucleic Acids       Date:  2022-07-13       Impact factor: 10.183

3.  The International Society of RNA Nanotechnology and Nanomedicine (ISRNN): The Present and Future of the Burgeoning Field.

Authors:  Morgan Chandler; Brittany Johnson; Emil Khisamutdinov; Marina A Dobrovolskaia; Joanna Sztuba-Solinska; Aliasger K Salem; Koen Breyne; Roger Chammas; Nils G Walter; Lydia M Contreras; Peixuan Guo; Kirill A Afonin
Journal:  ACS Nano       Date:  2021-10-22       Impact factor: 18.027

4.  Discrimination of RNA fiber structures using solid-state nanopores.

Authors:  Prabhat Tripathi; Morgan Chandler; Christopher Michael Maffeo; Ali Fallahi; Amr Makhamreh; Justin Halman; Aleksei Aksimentiev; Kirill A Afonin; Meni Wanunu
Journal:  Nanoscale       Date:  2022-05-16       Impact factor: 8.307

Review 5.  Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs).

Authors:  Weina Ke; Kirill A Afonin
Journal:  Adv Drug Deliv Rev       Date:  2021-06-16       Impact factor: 17.873

Review 6.  Nucleic acid nanoparticles (NANPs) as molecular tools to direct desirable and avoid undesirable immunological effects.

Authors:  M Brittany Johnson; Morgan Chandler; Kirill A Afonin
Journal:  Adv Drug Deliv Rev       Date:  2021-04-20       Impact factor: 17.873

Review 7.  RNA Drug Delivery Using Biogenic Nanovehicles for Cancer Therapy.

Authors:  Nuannuan Li; Yiying Sun; Yuanlei Fu; Kaoxiang Sun
Journal:  Front Pharmacol       Date:  2021-12-24       Impact factor: 5.810

8.  Simultaneous silencing of lysophosphatidylcholine acyltransferases 1-4 by nucleic acid nanoparticles (NANPs) improves radiation response of melanoma cells.

Authors:  Renata F Saito; Maria Cristina Rangel; Justin R Halman; Morgan Chandler; Luciana Nogueira de Sousa Andrade; Silvina Odete-Bustos; Tatiane Katsue Furuya; Alexis Germán Murillo Carrasco; Adriano B Chaves-Filho; Marcos Y Yoshinaga; Sayuri Miyamoto; Kirill A Afonin; Roger Chammas
Journal:  Nanomedicine       Date:  2021-06-24       Impact factor: 6.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.